Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:ARDX NASDAQ:KYMR NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsARDXArdelyx$6.55-1.0%$6.08$3.21▼$8.40$1.61B0.624.47 million shs254,852 shsKYMRKymera Therapeutics$82.56-1.8%$83.94$28.06▼$103.00$6.79B2.06684,883 shs69,366 shsPTGXProtagonist Therapeutics$100.87-2.5%$99.95$43.20▼$107.84$6.51B1.89764,581 shs138,537 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.21%+71.13%+99.19%ARDXArdelyx-2.51%-3.92%+6.96%-9.45%+82.60%KYMRKymera Therapeutics-2.30%+4.20%-1.12%+5.80%+179.68%PTGXProtagonist Therapeutics+4.17%+5.22%+4.74%+23.39%+140.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.67$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsARDXArdelyx$6.55-1.0%$6.08$3.21▼$8.40$1.61B0.624.47 million shs254,852 shsKYMRKymera Therapeutics$82.56-1.8%$83.94$28.06▼$103.00$6.79B2.06684,883 shs69,366 shsPTGXProtagonist Therapeutics$100.87-2.5%$99.95$43.20▼$107.84$6.51B1.89764,581 shs138,537 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.21%+71.13%+99.19%ARDXArdelyx-2.51%-3.92%+6.96%-9.45%+82.60%KYMRKymera Therapeutics-2.30%+4.20%-1.12%+5.80%+179.68%PTGXProtagonist Therapeutics+4.17%+5.22%+4.74%+23.39%+140.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.11Hold$111.87-2.78% DownsideARDXArdelyx 2.90Moderate Buy$15.70139.88% UpsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1043.05% UpsidePTGXProtagonist Therapeutics 2.80Moderate Buy$113.6912.72% UpsideCurrent Analyst Ratings BreakdownLatest ARDX, ACLX, KYMR, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/29/2026ACLXArcellx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral4/27/2026ACLXArcellx Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026KYMRKymera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ACLXArcellx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ARDXArdelyx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$22.29M301.95N/AN/A$6.96 per share16.53ARDXArdelyx$407.32M3.97N/AN/A$0.69 per share9.49KYMRKymera Therapeutics$39.21M173.19N/AN/A$19.42 per share4.25PTGXProtagonist Therapeutics$46.02M140.95N/AN/A$9.83 per share10.26Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%N/AARDXArdelyx-$61.60M-$0.23N/A13.09N/A-13.58%-38.11%-11.85%N/AKYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/APTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%N/ALatest ARDX, ACLX, KYMR, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million2/26/2026Q4 2025ACLXArcellx-$1.01-$1.01N/A-$1.01$13.40 million$1.65 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 million2/19/2026Q4 2025ARDXArdelyx$0.02-$0.01-$0.03-$0.01$118.04 million$125.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AARDXArdelyxN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.444.44ARDXArdelyx1.373.493.28KYMRKymera TherapeuticsN/A10.8110.81PTGXProtagonist TherapeuticsN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%ARDXArdelyx58.92%KYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%ARDXArdelyx5.30%KYMRKymera Therapeutics15.98%PTGXProtagonist Therapeutics5.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8058.48 million53.60 millionOptionableARDXArdelyx90247.03 million233.94 millionOptionableKYMRKymera Therapeutics17082.26 million69.11 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableARDX, ACLX, KYMR, and PTGX HeadlinesRecent News About These CompaniesInsider Selling: Protagonist Therapeutics (NASDAQ:PTGX) Director Sells 36,000 Shares of StockMay 11 at 9:09 PM | marketbeat.comAnalyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging HigherMay 11 at 10:26 AM | finance.yahoo.comState of New Jersey Common Pension Fund D Sells 20,969 Shares of Protagonist Therapeutics, Inc. $PTGXMay 11 at 5:00 AM | marketbeat.comNan Fung Trinity HK Ltd. Has $15.78 Million Stock Position in Protagonist Therapeutics, Inc. $PTGXMay 10 at 6:31 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Rating Increased to Strong-Buy at Wall Street ZenMay 9 at 2:35 AM | marketbeat.comProtagonist Therapeutics, Inc. Surprised Analysts With A Profit, And Analysts Boosted Their EPS ForecastsMay 9 at 1:30 AM | finance.yahoo.comIs It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?May 7, 2026 | finance.yahoo.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $137.00 Price Target at Citizens JmpMay 7, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $118.00 Price Target at WedbushMay 7, 2026 | americanbankingnews.comProtagonist Therapeutics: Q1 Earnings SnapshotMay 6, 2026 | chron.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $137.00May 6, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, Wedbush Analyst SaysMay 6, 2026 | marketbeat.comVanguard Group Inc. Purchases 1,156,461 Shares of Protagonist Therapeutics, Inc. $PTGXMay 6, 2026 | marketbeat.comProtagonist Therapeutics: Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | finanznachrichten.deProtagonist Therapeutics (NASDAQ:PTGX) Posts Earnings Results, Beats Expectations By $0.70 EPSMay 5, 2026 | marketbeat.comProtagonist Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | accessnewswire.comAProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from BrokeragesMay 5, 2026 | americanbankingnews.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Moderate Buy" from AnalystsMay 5, 2026 | marketbeat.comProtagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This StockMay 2, 2026 | insidermonkey.com331,164 Shares in Protagonist Therapeutics, Inc. $PTGX Bought by Jennison Associates LLCMay 2, 2026 | marketbeat.comM&T Bank Corp Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGXMay 1, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARDX, ACLX, KYMR, and PTGX Company DescriptionsArcellx NASDAQ:ACLXArcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Ardelyx NASDAQ:ARDX$6.54 -0.07 (-0.98%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Kymera Therapeutics NASDAQ:KYMR$82.56 -1.55 (-1.84%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$100.86 -2.64 (-2.55%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
